Compare MDV & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDV | IMUX |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | 12 | 66 |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.4M | 152.6M |
| IPO Year | N/A | 2013 |
| Metric | MDV | IMUX |
|---|---|---|
| Price | $15.58 | $1.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $18.00 | $4.80 |
| AVG Volume (30 Days) | 64.5K | ★ 1.8M |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | ★ 7.82% | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.13 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.80 | $0.51 |
| 52 Week High | $17.15 | $1.51 |
| Indicator | MDV | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 65.52 | 53.23 |
| Support Level | $14.03 | $1.05 |
| Resistance Level | N/A | $1.35 |
| Average True Range (ATR) | 0.33 | 0.11 |
| MACD | 0.13 | -0.01 |
| Stochastic Oscillator | 97.79 | 53.13 |
Modiv Industrial Inc is a pioneer in the direct-to-consumer commercial real estate product industry. It provides individual investors access to real estate and real estate-related investments designed to provide both income and long-term growth. The Company has invested in single-tenant income-producing properties. Its current business consists of owning, managing, operating, leasing, acquiring, investing in and disposing of commercial real estate assets utilized for industrial manufacturing, as well as a few non-core assets. All of the company's consolidated revenues are derived from company's consolidated real estate properties.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.